A
Agilent Technologies, Inc.

Agilent Technologies, Inc.A

Healthcare · Diagnostics & Research
177.17USD
+0.97%
Nov 05, 2026
A overview ready
Provider of advanced analytical instruments enabling pharmaceutical quality control
Agilent is a laboratory-tools enabler supplying chromatography, mass spectrometry, spectroscopy, pathology and diagnostic technologies, lab informatics, consumables, and lifecycle services used in pharmaceutical and biotech research, analytical development, quality control, and regulated testing.
Theme not measured
No economic group is assigned yet.
Price action is under distribution
Longer-term context reads early trend, with a near-term setup of breakout attempt.
Demanding valuation
The price embeds expectations that run ahead of what comparable businesses command.
Unremarkable fundamentals
Primary risk
Exposure to fluctuations in healthcare and research funding.
Market Nov 4Filing Jul 31Price action Nov 5Research Aug 3

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction7.1BusinessPerformance5.0BusinessQuality8.4Valuation2.9ThemeMomentum—Stable — Revenue is growing at a steady pace (+8.1% year over year). Diluted EPS is up 9% year over year ($1.28), but growth has slowed from +60%. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

Price action is under distribution
Longer-term context reads early trend, with a near-term setup of breakout attempt.
EntryEarly recovery

The structure is repairing early: weekly fast averages are being reclaimed and the daily chart is recovering constructively — an early-recovery entry profile.

Key Financials

Market Cap
$49.9B
Avg Volume (60D)
2.3M
60 sessions
Revenue Growth YoY
+6.7%
FY2025 vs FY2024
Gross Margin
+53.7%
Trailing twelve months
Operating Margin
+22.2%
Trailing twelve months
Free Cash Flow Yield
+2.5%
P/E
34.7x
EV / EBITDA
27.1x
EV / Sales
7.0x
Market metrics as of Nov 4, 2026
Financial results for the period ended Jul 31, 2026
Filed balance-sheet data as of Jul 31, 2026

Business Performance

Stable

Revenue is growing at a steady pace (+8.1% year over year). Diluted EPS is up 9% year over year ($1.28), but growth has slowed from +60%.

Latest reported: Q3 FY2026, ended Jul 31
Revenue growthGrowing
+8.1%
$1.88B in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. +9.4%
  2. +7.0%
  3. +10%
  4. +8.1%
Earnings growthSlowing
+8.5%
Diluted EPS $1.28 vs $1.18 a year earlier · GAAP
Diluted EPS YoY (GAAP), last 4 quarters
  1. n/a
  2. -3.6%
  3. +60%
  4. +8.5%
Operating marginExpanding
23.6%
+2.9 pp YoY

Business Quality

8.4 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

All three valuation perspectives agree this company is expensive.
Agilent Technologies, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of what comparable businesses command.

Company Research

Thesis
Agilent is a laboratory-tools enabler supplying chromatography, mass spectrometry, spectroscopy, pathology and diagnostic technologies, lab informatics, consumables, and lifecycle services used in pharmaceutical and biotech research, analytical development, quality control, and regulated testing.
Opportunity
Moderate opportunity
Pharma and biotechnology investment in the analytical instrumentation, consumables, software, and validated laboratory workflows required to characterize molecules, support development, demonstrate quality, and release regulated products.
Key risk
Exposure to fluctuations in healthcare and research funding.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Diagnostics & Research
What they do

Agilent Technologies provides application-focused solutions and analytical instruments to the life sciences, diagnostics, and applied chemical markets globally, operating through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.

How it earns

The company generates revenue primarily through transactional sales of instruments, consumables, and related services.

Products & services
Liquid chromatography systems and components
Liquid chromatography mass spectrometry systems
Analytical instruments for peptide characterization and release testing
Customers & end markets
Life sciences companies
Diagnostics providers
Applied chemical market participants
Market position

Agilent is a leader in analytical instrumentation and solutions for life sciences and diagnostics.

Demand drivers
Medium cyclicality

Demand is influenced by healthcare and research funding cycles but also benefits from steady innovation-driven needs.